Anzeige
Mehr »
Login
Freitag, 04.04.2025 Börsentäglich über 12.000 News von 693 internationalen Medien
Warum Almonty Industries zum Schlüsselplayer für NATO-Staaten wird
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2JRKN | ISIN: KYG0520K1094 | Ticker-Symbol: 2VJ
Tradegate
03.04.25
07:41 Uhr
0,770 Euro
+0,015
+1,99 %
Branche
Biotechnologie
Aktienmarkt
ASIEN
1-Jahres-Chart
ASCLETIS PHARMA INC Chart 1 Jahr
5-Tage-Chart
ASCLETIS PHARMA INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,7200,79508:28
0,7300,77008:25

Aktuelle News zur ASCLETIS PHARMA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiASCLETIS-B (01672): NEXT DAY DISCLOSURE RETURN-
MoASCLETIS-B (01672): INSIDE INFORMATION - ASCLETIS ANNOUNCES POSITIVE INTERIM RESULTS FROM ITS U.S. PHASE IB TRIAL WITH ASC30, A POTENTIALLY FIRST-IN-CLASS ...1
26.03.Ascletis slashes funding for former core programs in pivot to obesity7
26.03.ASCLETIS-B (01672): ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2024 AND CHANGE IN THE USE OF PROCEEDS1
13.03.ASCLETIS-B (01672): NOTICE OF BOARD MEETING2
12.03.Ascletis Announces Positive ASC47 Phase Ib Pharmacokinetic & Weight Loss Data From Australia Studies348BEIJING (dpa-AFX) - Ascletis Pharma Inc. (ASCLF.PK) announced promising pharmacokinetic and weight loss data from its ASC47 Phase Ib single subcutaneous injection studies conducted in Australia....
► Artikel lesen
12.03.Ascletis Pharma Inc.: Ascletis Announces Positive Topline Results of Phase Ib Studies of ASC47 Monotherapy in Australia and U.S. FDA Clearance of IND Application for ASC47 in Combination with Semaglutide71ASC47, an adipose-targeted muscle-preserving weight loss drug candidate for the treatment of obesity, demonstrated a half-life of up to 26 days and 40 days, respectively...
► Artikel lesen
ASCLETIS PHARMA Aktie jetzt für 0€ handeln
12.03.ASCLETIS-B (01672): INSIDE INFORMATION - ASCLETIS ANNOUNCES POSITIVE TOPLINE RESULTS OF PHASE IB STUDIES OF ASC47 MONOTHERAPY IN AUSTRALIA AND U.S. FDA ...2
19.02.Ascletis' swift surge into obesity continues with competitive oral GLP-1 data3
19.02.Ascletis Pharma Reports Positive Interim Phase 1b Data For ASC30 To Treat Obesity306BEIJING (dpa-AFX) - Ascletis Pharma Inc. (ASCLF.PK) Wednesday reported positive interim results from the Phase 1b study of ASC30 for the treatment of obesity.The Phase Ib multiple ascending...
► Artikel lesen
19.02.Ascletis Pharma Inc.: Ascletis Announces Positive Interim Results from First Two Cohorts of U.S. Phase Ib Multiple Ascending Dose Study of Small Molecule Oral GLP-1R Agonist ASC30114- ASC30 oral once-daily tablet demonstrated a 6.3% mean body weight reduction from baseline after 28-day treatment in multiple ascending dose (MAD) cohort 2 (weekly...
► Artikel lesen
19.02.ASCLETIS-B (01672): INSIDE INFORMATION - ASCLETIS ANNOUNCES POSITIVE INTERIM RESULTS FROM FIRST TWO COHORTS OF U.S. PHASE IB MULTIPLE ASCENDING DOSE STUDY ...2
13.02.ASCLETIS-B (01672): NEXT DAY DISCLOSURE RETURN1
03.02.ASCLETIS-B (01672): POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON FEBRUARY 3, 2025-
23.01.ASCLETIS-B (01672): NEXT DAY DISCLOSURE RETURN6
21.01.Ascletis Pharma Inc.: Ascletis Announces Positive Results from U.S. Phase Ia Single Ascending Dose Study of Small Molecule Oral GLP-1R Agonist ASC30 and Provides Program Update119ASC30 oral tablet demonstrated dose-proportional pharmacokinetic (PK) properties and a long half-life (t1/2) up to 60 hours in the single ascending dose (SAD)...
► Artikel lesen
21.01.ASCLETIS-B (01672): VOLUNTARY ANNOUNCEMENT - ASCLETIS ANNOUNCES POSITIVE RESULTS FROM U.S. PHASE IA SINGLE ASCENDING DOSE STUDY OF SMALL MOLECULE ORAL ...2
15.01.ASCLETIS-B (01672): NEXT DAY DISCLOSURE RETURN-
14.01.ASCLETIS-B (01672): FORM OF PROXY FOR THE EXTRAORDINARY GENERAL MEETING TO BE HELD ON MONDAY, FEBRUARY 3, 20251
14.01.ASCLETIS-B (01672): NOTICE OF EXTRAORDINARY GENERAL MEETING2
Seite:  Weiter >>
42 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1